Sweden · Delayed Price · Currency is SEK AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of SEK 2.87 trillion. The enterprise value is 3.09 trillion.
| Market Cap | 2.87T |
| Enterprise Value | 3.09T |
Important Dates
The last earnings date was Tuesday, February 10, 2026.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | Feb 19, 2026 |
Share Statistics
| Current Share Class | 1.55B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 66.74% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 30.45 and the forward PE ratio is 19.30.
| PE Ratio | 30.45 |
| Forward PE | 19.30 |
| PS Ratio | 5.30 |
| PB Ratio | 6.39 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 26.47 |
| P/OCF Ratio | 21.37 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.06, with an EV/FCF ratio of 28.51.
| EV / Earnings | 32.80 |
| EV / Sales | 5.72 |
| EV / EBITDA | 17.06 |
| EV / EBIT | 23.50 |
| EV / FCF | 28.51 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.61.
| Current Ratio | 0.94 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 1.51 |
| Debt / FCF | 2.52 |
| Interest Coverage | 10.47 |
Financial Efficiency
Return on equity (ROE) is 22.84% and return on invested capital (ROIC) is 16.48%.
| Return on Equity (ROE) | 22.84% |
| Return on Assets (ROA) | 8.19% |
| Return on Invested Capital (ROIC) | 16.48% |
| Return on Capital Employed (ROCE) | 17.12% |
| Weighted Average Cost of Capital (WACC) | 5.17% |
| Revenue Per Employee | 5.63M |
| Profits Per Employee | 980,712 |
| Employee Count | 94,300 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, AstraZeneca has paid 19.99 billion in taxes.
| Income Tax | 19.99B |
| Effective Tax Rate | 17.49% |
Stock Price Statistics
The stock price has increased by +15.09% in the last 52 weeks. The beta is 0.19, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +15.09% |
| 50-Day Moving Average | 1,750.46 |
| 200-Day Moving Average | 1,563.23 |
| Relative Strength Index (RSI) | 57.76 |
| Average Volume (20 Days) | 352,553 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of SEK 541.41 billion and earned 94.25 billion in profits. Earnings per share was 60.28.
| Revenue | 541.41B |
| Gross Profit | 442.36B |
| Operating Income | 131.73B |
| Pretax Income | 114.31B |
| Net Income | 94.25B |
| EBITDA | 177.71B |
| EBIT | 131.73B |
| Earnings Per Share (EPS) | 60.28 |
Balance Sheet
The company has 52.71 billion in cash and 273.78 billion in debt, with a net cash position of -221.07 billion.
| Cash & Cash Equivalents | 52.71B |
| Total Debt | 273.78B |
| Net Cash | -221.07B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 449.06B |
| Book Value Per Share | 289.23 |
| Working Capital | -17.46B |
Cash Flow
In the last 12 months, operating cash flow was 134.34 billion and capital expenditures -25.90 billion, giving a free cash flow of 108.44 billion.
| Operating Cash Flow | 134.34B |
| Capital Expenditures | -25.90B |
| Free Cash Flow | 108.44B |
| FCF Per Share | n/a |
Margins
Gross margin is 81.71%, with operating and profit margins of 24.33% and 17.41%.
| Gross Margin | 81.71% |
| Operating Margin | 24.33% |
| Pretax Margin | 21.11% |
| Profit Margin | 17.41% |
| EBITDA Margin | 32.82% |
| EBIT Margin | 24.33% |
| FCF Margin | 20.03% |
Dividends & Yields
This stock pays an annual dividend of 29.30, which amounts to a dividend yield of 1.59%.
| Dividend Per Share | 29.30 |
| Dividend Yield | 1.59% |
| Dividend Growth (YoY) | -13.19% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 47.39% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 1.66% |
| Earnings Yield | 3.28% |
| FCF Yield | 3.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.24 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.24 |
| Piotroski F-Score | 7 |